<DOC>
	<DOC>NCT01175707</DOC>
	<brief_summary>This is a randomized, open-label, multi-center, phase 4 study designed to compare intravenous (IV) daptomycin and IV vancomycin administered in a home infusion setting for the treatment of complicated skin and skin structure infections (cSSSI) due to Gram-positive bacteria in participants who are prescribed vancomycin for 7 to 14 days and who are planning to receive vancomycin in a home-infusion setting.</brief_summary>
	<brief_title>Study Comparing Cubicin With Vancomycin in Treatment of Participants With Complicated Skin and Skin Structure Infections in a Home Infusion Setting</brief_title>
	<detailed_description>This is a randomized, open-label, multi-center, phase 4 study. The overall goals of this study are to compare intravenous (IV) daptomycin and IV vancomycin administered in a home infusion setting for the treatment of cSSSI due to Gram-positive bacteria in participants who are prescribed vancomycin for 7-14 days and who are planning to receive vancomycin in a home infusion setting. Study objectives include evaluation of clinical and resource utilization endpoints and economic analysis from the perspective of the home infusion provider.</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Daptomycin</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<criteria>Complicated skin or skin structure infection (cSSSI) Intravenous vancomycin home infusion ordered for 714 days Pregnant or lactating female Concurrently receiving other systemic antibiotics with gram positive activity Known or suspected allergy or hypersensitivity to daptomycin or vancomycin Known or suspected vancomycinresistant enterococci (VRE) Known or suspected osteomyelitis, pneumonia, bacteremia, endocarditis, or urinary tract infection Known or suspected human immunodeficiency virus (HIV), cancer, or autoimmune disease such as lupus Receiving systemic concomitant immunosuppressive agents such as chemotherapy, corticosteroids, tacrolimus, sirolimus, or cyclosporine, during the duration of the study Requirement for nonstudy gram positive systemic antibiotics Known to be allergic or intolerant to intravenous vancomycin or daptomycin Participants with known or suspected creatinine clearance (CLcr) &lt; 30 milliliters per minute (mL/min) In skilled nursing facility In hospice or admission to hospice is planned</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>